PT2632935T - Processo para o fabrico de degarelix e seus intermediários - Google Patents

Processo para o fabrico de degarelix e seus intermediários

Info

Publication number
PT2632935T
PT2632935T PT117767459T PT11776745T PT2632935T PT 2632935 T PT2632935 T PT 2632935T PT 117767459 T PT117767459 T PT 117767459T PT 11776745 T PT11776745 T PT 11776745T PT 2632935 T PT2632935 T PT 2632935T
Authority
PT
Portugal
Prior art keywords
degarelix
intermediates
manufacture
Prior art date
Application number
PT117767459T
Other languages
English (en)
Portuguese (pt)
Inventor
Fomsgaard Jens
Holbech Rasmussen Jon
Hansen Stefan
Hedengran Rasmussen Palle
Oliver Wachs Wolfgang
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PT2632935T publication Critical patent/PT2632935T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
PT117767459T 2010-10-27 2011-10-26 Processo para o fabrico de degarelix e seus intermediários PT2632935T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10189032A EP2447276A1 (en) 2010-10-27 2010-10-27 Process for the manufacture of Degarelix and its intermediates

Publications (1)

Publication Number Publication Date
PT2632935T true PT2632935T (pt) 2016-11-02

Family

ID=43531147

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117767459T PT2632935T (pt) 2010-10-27 2011-10-26 Processo para o fabrico de degarelix e seus intermediários

Country Status (26)

Country Link
US (2) US9090656B2 (es)
EP (2) EP2447276A1 (es)
JP (1) JP6007187B2 (es)
KR (1) KR101904808B1 (es)
CN (1) CN103180335B (es)
AU (1) AU2011322618B2 (es)
BR (1) BR112013010360B1 (es)
CA (1) CA2815270A1 (es)
DK (1) DK2632935T3 (es)
ES (1) ES2606753T3 (es)
HR (1) HRP20161315T1 (es)
HU (1) HUE030184T2 (es)
IL (1) IL225687A (es)
JO (1) JO3243B1 (es)
LT (1) LT2632935T (es)
MX (1) MX343058B (es)
NZ (1) NZ609064A (es)
PL (1) PL2632935T3 (es)
PT (1) PT2632935T (es)
RS (1) RS55193B1 (es)
RU (1) RU2602042C2 (es)
SA (1) SA111320880B1 (es)
SI (1) SI2632935T1 (es)
TW (1) TWI515201B (es)
WO (1) WO2012055905A1 (es)
ZA (1) ZA201302670B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
RU2536245C2 (ru) * 2009-05-01 2014-12-20 Ферринг Б.В. Композиция для лечения рака предстательной железы
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
DK2632934T3 (en) 2010-10-27 2017-01-23 Ferring Bv Process for the preparation of Degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
DK2854831T3 (da) 2012-06-01 2024-10-14 Ferring B V Fremstilling af degarelix
CN103992378A (zh) * 2013-11-01 2014-08-20 杭州诺泰制药技术有限公司 一种制备醋酸地加瑞克的方法
CN106589071B (zh) * 2016-12-12 2020-09-08 江苏诺泰澳赛诺生物制药股份有限公司 一种地加瑞克的合成方法
CN109748954B (zh) * 2017-11-06 2022-03-01 正大天晴药业集团股份有限公司 一种地加瑞克的纯化方法
CN107955061B (zh) * 2017-11-15 2021-07-30 连云港恒运药业有限公司 地加瑞克关键中间体的制备方法
CN109929007B (zh) * 2017-12-15 2023-07-28 连云港恒运药业有限公司 地加瑞克关键二肽中间体的制备方法
CN110330552B (zh) * 2019-08-14 2021-03-16 凯莱英生命科学技术(天津)有限公司 醋酸地加瑞克的合成方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5516887A (en) 1991-04-25 1996-05-14 Romano Deghenghi Luteinizing hormone releasing hormone antagonist peptides
DE69330107T3 (de) 1992-02-12 2004-12-30 Daikyo Gomu Seiko, Ltd. Medizinisches Gerät
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
AU1590699A (en) 1997-11-20 1999-06-15 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of gnrh peptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
ES2589322T3 (es) 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
WO2010121835A1 (en) * 2009-04-24 2010-10-28 Polypeptide Laboratories A/S Method for the manufacture of degarelix
RU2536245C2 (ru) 2009-05-01 2014-12-20 Ферринг Б.В. Композиция для лечения рака предстательной железы
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
DK2632934T3 (en) 2010-10-27 2017-01-23 Ferring Bv Process for the preparation of Degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013012783A1 (en) 2011-07-15 2013-01-24 Joseph Raymond E Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
TWI515201B (zh) 2016-01-01
BR112013010360A2 (pt) 2016-08-02
AU2011322618B2 (en) 2015-05-21
HUE030184T2 (en) 2017-04-28
SA111320880B1 (ar) 2015-03-30
EP2447276A1 (en) 2012-05-02
EP2632935A1 (en) 2013-09-04
JO3243B1 (ar) 2018-03-08
KR20130127443A (ko) 2013-11-22
EP2632935B1 (en) 2016-09-21
RS55193B1 (sr) 2017-01-31
MX2013004320A (es) 2013-12-02
KR101904808B1 (ko) 2018-10-05
US9822146B2 (en) 2017-11-21
NZ609064A (en) 2015-01-30
JP2013540793A (ja) 2013-11-07
JP6007187B2 (ja) 2016-10-12
US20130281661A1 (en) 2013-10-24
IL225687A0 (en) 2013-06-27
CN103180335B (zh) 2016-04-06
ZA201302670B (en) 2015-12-23
HRP20161315T1 (hr) 2016-12-02
CN103180335A (zh) 2013-06-26
BR112013010360B1 (pt) 2023-03-21
AU2011322618A1 (en) 2013-05-02
DK2632935T3 (en) 2016-11-14
SI2632935T1 (sl) 2017-01-31
CA2815270A1 (en) 2012-05-03
RU2013118446A (ru) 2014-12-10
WO2012055905A1 (en) 2012-05-03
ES2606753T3 (es) 2017-03-27
LT2632935T (lt) 2016-10-25
IL225687A (en) 2017-06-29
TW201305186A (zh) 2013-02-01
MX343058B (es) 2016-10-24
US9090656B2 (en) 2015-07-28
US20160145301A1 (en) 2016-05-26
RU2602042C2 (ru) 2016-11-10
PL2632935T3 (pl) 2017-01-31

Similar Documents

Publication Publication Date Title
ZA201302670B (en) Process for the manufacture of degarelix and its intermediates
RS55457B1 (sr) Postupak za proizvodnju degareliksa i njegovih intermedijara
EP2552874A4 (en) PROCESS FOR PREPARING HEXAFLUOR-2 BUTENE
EP2558432A4 (en) METHOD FOR THE PRODUCTION OF TETRAFLUOROLEFINES
HK1167865A1 (en) Method for the manufacture of degarelix
HUP1000330A2 (en) Process for the preparation of dronedarone and the novel intermediates
PL2627656T3 (pl) Sposób wytwarzania dihydropterydynonów i ich produktów pośrednich
IL221441A0 (en) Process for preparing entecavir and its intermediates
EP2630143A4 (en) PROCESS FOR THE PRODUCTION OF RIVAROXABAN AND INTERMEDIATE PRODUCTS THEREOF
IL216942A0 (en) Process for the manufacture of alkenones
EP2528923A4 (en) METHOD FOR PRODUCING DARUNAVIR AND DARUNAVIR INTERMEDIATE PRODUCTS
GB201004096D0 (en) Production of polyhydroalkanoates
EP2578725A4 (en) COATED ELEMENT AND METHOD FOR PRODUCING THE SAME
SI2576556T1 (sl) Postopek za sintezo karbonukleozida in intermediatov za uporabo v tem postopku
HUE044066T2 (hu) Eljárás metilén-difenil-diizocianát elõállítására
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
EP2643308A4 (en) PROCESS FOR THE PREPARATION OF TAUROLIDINE AND ITS INTERMEDIATE PRODUCTS
PT2603319E (pt) Processo para a preparação de uretanos
PT2390246T (pt) Processo para a preparação de aminaftona
PT2598504E (pt) Novo processo de fabrico de dimiracetam
EG27000A (en) Process for the preparation of ibodutant (MEN15596) and related intermediates
IL224304A (en) A process for making dichlorobulben
IL220477A (en) A process for making Darunavir and intermediates of Daronavir
PL391702A1 (pl) Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny